Novo Nordisk A/S · ISIN: US6701002056

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi &...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 24.03.2025 | 17:58
24 March 2025 05:58PM
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi &...
© BusinessWire
24 March 2025 01:00PM
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
The Wegovy® savings offer is good for all dose strengths of Wegovy® Eligible cash-paying patients can redeem this offer at the retail pharmacy of their choicePLAINSBORO, N.J., March 24, 2025 /PRNewswire/ -- Today, Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semagluti...
© PR Newswire
24 March 2025 10:45AM
The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to cont...
© PR Newswire
23 March 2025 01:12PM
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK, March 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive...
© PR Newswire
22 March 2025 10:17PM
NVO Deadline: Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024. Novo describes itself as a “healthcare company, focused on the research, development, manufacturing, and distribution of p...
© BusinessWire
22 March 2025 02:21PM
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Novo Nordisk between November 2, 2022 and December 19, 2024 and would like to discuss your legal rights...
© PR Newswire
21 March 2025 10:45AM
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO
NEW YORK, March 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover lo...
© PR Newswire
20 March 2025 10:04AM
Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
NEW YORK, March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to cont...
© PR Newswire
19 March 2025 02:58PM
NVO Investors are Reminded of Final Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, March 19, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE: NVO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Secu...
© PR Newswire
18 March 2025 11:47PM
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK, March 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive...
© PR Newswire
18 March 2025 10:45AM
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO
NEW YORK, March 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover lo...
© PR Newswire
17 March 2025 05:28PM
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ: NVO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encou...
© PR Newswire
17 March 2025 10:45AM
Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact The Gross Law Firm
NEW YORK, March 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to cont...
© PR Newswire
13 March 2025 11:49PM
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK, March 13, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive...
© PR Newswire
13 March 2025 03:31PM
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo Nordisk between November 2, 2022 and December 19, 2024 and would like to discuss your legal rights, call Faruqi & F...
© PR Newswire
13 March 2025 10:45AM
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO
NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to cont...
© PR Newswire
12 March 2025 10:45AM
Levi & Korsinsky Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
NEW YORK, March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover lo...
© PR Newswire
11 March 2025 05:23PM
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
NEW YORK, March 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encour...
© PR Newswire
10 March 2025 10:45AM
NVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to cont...
© PR Newswire
07 March 2025 11:46AM
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover los...
© PR Newswire
06 March 2025 10:36PM
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK, March 6, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive...
© PR Newswire
06 March 2025 11:45AM
The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to conta...
© PR Newswire
05 March 2025 04:22PM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo Nordisk between November 2, 2022 and December 19, 2024 and would like to discuss your legal rights, call Faruqi & F...
© PR Newswire
05 March 2025 02:00PM
Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients
NovoCare® Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of $499 per month for cash-paying patients While 90% of patients taking Wegovy ® have a co-pay of $0 to $25 per month, this offer was designed to support cash-paying patients without insurance coverage Amidst the dan...
© PR Newswire
04 March 2025 11:45AM
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S(NVO) Shareholders
NEW YORK, March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover los...
© PR Newswire
03 March 2025 07:40PM
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encourage...
© PR Newswire
03 March 2025 11:45AM
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO
NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to conta...
© PR Newswire
28 February 2025 06:01PM
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK, Feb. 28, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive...
© PR Newswire
28 February 2025 03:30PM
Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug - Hagens Berman
SAN FRANCISCO, Feb. 28, 2025 /PRNewswire/ -- Novo Nordisk A/S (NYSE: NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental obesity treatment, CagriSema.  Hage...
© PR Newswire
28 February 2025 11:45AM
March 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover los...
© PR Newswire
27 February 2025 11:45AM
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - NVO
NEW YORK, Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to conta...
© PR Newswire
25 February 2025 11:45AM
March 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover los...
© PR Newswire
24 February 2025 11:45AM
Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact The Gross Law Firm
NEW YORK, Feb. 24, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contac...
© PR Newswire
22 February 2025 05:00PM
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK, Feb. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (...
© PR Newswire
21 February 2025 11:45AM
Investors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover los...
© PR Newswire
20 February 2025 11:45AM
Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - NVO
NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to conta...
© PR Newswire
19 February 2025 12:21AM
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encoura...
© PR Newswire
17 February 2025 10:32PM
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK, Feb. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (...
© PR Newswire
14 February 2025 11:45AM
Investors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover los...
© PR Newswire
13 February 2025 11:45AM
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NVO
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to conta...
© PR Newswire
13 February 2025 01:01AM
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK, Feb. 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (...
© PR Newswire
11 February 2025 11:45AM
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover los...
© PR Newswire
10 February 2025 09:33PM
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Feb. 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE: NVO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Secur...
© PR Newswire
10 February 2025 11:45AM
The Gross Law Firm Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to conta...
© PR Newswire
09 February 2025 10:00PM
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged v...
© BusinessWire
07 February 2025 10:40PM
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE: NVO) and certain of its officers....
© PR Newswire
07 February 2025 07:07PM
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (t...
© PR Newswire
07 February 2025 04:29PM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Novo Nordisk between November 2, 2022 and December 19, 2024 and would like to discuss your legal rights...
© PR Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.